Menu Search
Equities

Harmony Biosciences Holdings Inc

60H:BER

Harmony Biosciences Holdings Inc

Actions
  • Price (EUR)31.86
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 28 2023 07:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol. It is also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.

  • Revenue in USD (TTM)681.88m
  • Net income in USD122.63m
  • Incorporated2017
  • Employees246.00
  • Location
    Harmony Biosciences Holdings Inc630 W Germantown Pike, Suite 215PLYMOUTH MEETING 19462United StatesUSA
  • Phone+1 (484) 539-9800
  • Fax+1 (302) 655-5049
  • Websitehttps://www.harmonybiosciences.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		HRMY:NMQ since
announced		Transaction
value
Epygenix Therapeutics IncDeal completed30 Apr 202430 Apr 2024Deal completed13.61%680.00m
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.